Photospectra Health Sciences Inc. was founded by Dr Graham Merry to research treatment of dry AMD with a novel therapeutic option – Photobiomodulation (PBM). There is a huge unmet need for safe and effective treatments for dry AMD.
Photospectra was responsible for ensuring the timely completion of TORPA – the first prospective study of PBM for dry AMD in Canada and the USA.
Photospectra was incorporated federally in Canada in 2009.
Dr. Graham Merry
Dr Merry graduated in Medicine from The Royal London Medical College, London, U.K. in 1982. He completed his registration year in the UK before moving to Canada where he practiced with the Under serviced Area Program in Northern Ontario.
He attended 2 years of Ophthalmology Residency at The University of Toronto.
He is in private practice at various primary ophthalmology clinics throughout the GTA and Barrie areas.
Dr Merry has been a consultant to the biotechnology industry especially in the area of AMD and has been principal investigator for several studies.
For the last five years Dr. Merry has been dedicated to evaluating, researching and providing treatments for patients with dry AMD.
He shares a commitment, dedication and vision with Drs Dotson and Devenyi to research with a well conceived clinical trial whether PBM will be a new, effective, safe and affordable treatment for patients with dry AMD.
“I am very fortunate to have had the opportunity to work with Dr Dotson and Dr Devenyi in this area, they are both brilliant scientists and clinicians and we all share the same ideals and aspirations to show through proper scientific studies that PBM is an effective treatment not just in Macular Degeneration but in many other areas of Ophthalmology and Medicine.”
CHIEF MEDICAL AND SCIENTIFIC OFFICER:
Dr. Robert Dotson
Dr. Dotson obtained his M.D. from the University of Tennessee in 1974. He obtained his board certification in Ophthalmology in 1980.
He undertook a fellowship in Anterior Segment Surgery. He has served with the US Army as Chief of Ophthalmology at Irwin Army Hospital.
Dr. Dotson has been active in training Ophthalmologists and a pioneer for many years in researching and developing PBM for applications in Ophthalmology.
He has served as consultant to numerous commercial companies and academic programs. He is an international lecturer and holds six patents in the field of Ophthalmology and Photobiomodulation.
CLINICAL TRIAL ADVISOR:
Dr. Robert Devenyi
Dr. Robert G. Devenyi graduated summa cum laude from the University of Toronto School of Medicine. He then completed his internship and his Ophthalmology residency at the University of Toronto affiliated hospitals, followed by a fellowship in vitreoretinal surgery at the Medical College of Wisconsin.
Dr. Devenyi then returned to Toronto to join the staff of the University of Toronto.
He is currently Professor of Ophthalmology and Vision Sciences at the University of Toronto and Ophthalmologist-in-Chief and Director of Retinal Services at the University Health Network.
Dr. Devenyi is an internationally renowned Retinal Surgeon with over 80 publications. He is a reviewer for national and international ophthalmology publications.
He is Team Ophthalmologist, The Toronto Maple Leafs, The National Hockey League.
“ I am pleased to be involved as a principal investigator and advisor to Photospectra in its pilot clinical study (TORPA) to assess PBM as a new treatment option for dry AMD.”